Synthetic organic

evixapodlin.

InformationEvobrutinib (M-2951) Evobrutinib (M-2951, MSC-2364447C) is a highly selective BTK inhibitor with an IC50 of 37.9 nM. It has potential anti-neoplastic activity.TargetsBTK (Cell-free assay) 37.9 nMIn vitroEvobrutinib can inhibit the

InformationEvobrutinib (M-2951) Evobrutinib (M-2951, MSC-2364447C) is a highly selective BTK inhibitor with an IC50 of 37.9 nM. It has potential anti-neoplastic activity.TargetsBTK (Cell-free assay) 37.9 nMIn vitroEvobrutinib can inhibit the

InformationEvobrutinib (M-2951) Evobrutinib (M-2951, MSC-2364447C) is a highly selective BTK inhibitor with an IC50 of 37.9 nM. It has potential anti-neoplastic activity.TargetsBTK (Cell-free assay) 37.9 nMIn vitroEvobrutinib can inhibit the

InformationEvobrutinib (M-2951) Evobrutinib (M-2951, MSC-2364447C) is a highly selective BTK inhibitor with an IC50 of 37.9 nM. It has potential anti-neoplastic activity.TargetsBTK (Cell-free assay) 37.9 nMIn vitroEvobrutinib can inhibit the

InformationEvobrutinib (M-2951) Evobrutinib (M-2951, MSC-2364447C) is a highly selective BTK inhibitor with an IC50 of 37.9 nM. It has potential anti-neoplastic activity.TargetsBTK (Cell-free assay) 37.9 nMIn vitroEvobrutinib can inhibit the

evocalcet.

evocalcet.

evodenoson.

evodenoson.

EVP-21.

EVP-21.